Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20053018HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS20024255HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS20053251HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS20053379HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS20024684HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS20030898HPVENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS44023867HTLV-1ENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS44005535HTLV-1ENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS44009769HTLV-1ENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TVIS44018019HTLV-1ENSG00000154975.14protein_codingCA10NoNo56934Q9NS85
TCGA Plot Options
Drug Information
GeneCA10
DrugBank IDDB00909
Drug NameZonisamide
Target IDBE0003631
UniProt IDQ9NS85
Regulation Typeinhibitor
PubMed IDs19703035; 18537527; 18782051; 17762320; 17582922
CitationsDe Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x.@@Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 .@@Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75.@@Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40.@@Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7.
GroupsApproved; Investigational
Direct ClassificationBenzisoxazoles
SMILESNS(=O)(=O)CC1=NOC2=CC=CC=C12
Pathways
PharmGKBPA451978
ChEMBLCHEMBL750